Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma

NCT04280328 is registered in ClinicalTrials.gov with Corvus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04280328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04280328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Corvus Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 20, 2020
Completion date
March 1, 2022
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma